Four biotech firms secure Series B funding and open new hiring opportunities

Biotech companies that closed Series B financing rounds this year are actively recruiting as they expand their operations.

Atavistik Bio, based in Cambridge, Massachusetts, announced a $40 million extension to its Series B round. The firm is pursuing allosteric drug candidates, including an oral AKT1 inhibitor for hereditary hemorrhagic telangiectasia and a JAK2‑targeted program for myeloproliferative neoplasms, and it maintains a research collaboration with Pfizer.

The broader group includes a company that raised more than $100 million and another that recently secured a partnership with a major pharmaceutical partner, underscoring the sector’s momentum and the demand for talent across drug discovery and development functions.